智通财经APP讯,维立志博-B(09887)发布公告,LBL-034(GPRC5D/CD3双特异性抗体)I期数据亮眼,II期试验首例患者成功用药。这标志着集团LBL-034临床研究取得里程碑成就,为推进后续临床试验奠定坚实基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.